Targeting glioblastoma with a first-in-class BRD8 molecular glue degrader and temozolomide
Active Project Grant Awarded Last action
- Award ID
- HT9425261E344
- Recipient
-
Sanford Burnham Prebys Medical Discovery Institute UEI PHMKYKKJLQS1
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $140,000
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 12% complete
- Place of performance
- La Jolla, CA 92037, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded Sanford Burnham Prebys Medical Discovery Institute $140,000 on August 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to target glioblastoma with a first-in-class BRD8 molecular glue degrader combined with temozolomide. The award funds research activities at the institute's La Jolla, California location through July 31, 2028. The program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative medical solutions, with typical award periods ranging from three to four years and award amounts from $100,000 to $20 million depending on funding priorities and project scope.
Quick answers
Who received award HT9425261E344?
HT9425261E344 was awarded to Sanford Burnham Prebys Medical Discovery Institute by Defense Health Agency (Department of Defense) on August 1, 2026.
How much is award HT9425261E344 worth?
$140,000 has been obligated on HT9425261E344.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award